Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Avalon GloboCare ( (ALBT) ) is now available.
Avalon GloboCare announced significant advancements in Q3 2025 for its KetoAir™ breathalyzer, including a new health program for first responders in Nevada and international expansion into the UK. These initiatives, along with showcasing at the London Health Optimization Summit, highlight Avalon’s strategic positioning in the global metabolic health market, aiming to meet the growing demand for health monitoring tools.
More about Avalon GloboCare
Avalon GloboCare Corp. is a developer of precision diagnostic consumer products and focuses on advancing intellectual property in cellular therapy. The company markets the KetoAir™ breathalyzer device, registered with the U.S. Food and Drug Administration, and plans to expand its diagnostic uses. Avalon also owns and operates commercial real estate.
Average Trading Volume: 52,873
Technical Sentiment Signal: Sell
Current Market Cap: $6.29M
For an in-depth examination of ALBT stock, go to TipRanks’ Overview page.